Tenofovir's effect on bone density in chronic hepatitis B
Treatments studied
Part of Bones, joints & muscles, Infections clinical trials.
This study looks at how long-term use of the hepatitis B medicine Tenofovir (TDF) affects bone density. It may help you understand potential bone health risks if you've been taking TDF for over five years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have chronic hepatitis B (HBV-positive).
- You have been taking Tenofovir (TDF) for more than five years.
- You do not have other chronic liver diseases.
- You do not have chronic kidney disease (any cause).
- You are not taking interferon or multiple hepatitis B medicines together.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines how long-term use of the hepatitis B medicine Tenofovir (TDF) affects kidney function. It may help doctors understand how to better monitor and protect your kidneys while treating hepatitis B.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This study tests if switching your current hepatitis B antiviral to Tenofovir Alafenamide (TAF) keeps your new liver working well with fewer side effects. It is for people who had a liver transplant due to hepatitis B and have stable liver function for at least a year.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Hear when a new Bone Density trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.